Article
A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia.
Blood advances - 28 May 2024
Levis Mark, Perl Alexander, Schiller Gary, Fathi Amir T, Roboz Gail, Wang Eunice S, Altman Jessica, Rajkhowa Trivikram, Ando Makoto, Suzuki Takeaki, Subach Ruth Ann, Maier Gary, Madden Timothy, Johansen Mary, Cheung Kin, Kurman Michael, Smith Catherine
Abstract excerpt
ABSTRACT: FLT3 tyrosine kinase inhibitors (TKIs) have clinical efficacy for patients with FLT3-mutated AML (acute myeloid leukemia), but their impact is limited by resistance in the setting of monotherapy and by tolerability problems when used in combination therapies. FF-10101 is a novel compound that covalently binds to a cysteine residue near the active site of FLT3, irreversibly inhibiting receptor signaling....
Topics
- Humans
- fms-Like Tyrosine Kinase 3
- Leukemia, Myeloid, Acute
- Middle Aged
- Female
- Male
- Adult
- Aged
- Protein Kinase Inhibitors
- Recurrence